|
Status |
Public on Feb 01, 2016 |
Title |
UTX inhibition as selective epigenetic therapy against TAL1-driven T cell acute lymphoblastic leukemia |
Organism |
Homo sapiens |
Experiment type |
Genome binding/occupancy profiling by high throughput sequencing Third-party reanalysis
|
Summary |
We performed ChIP-Seq in Jurkat T-ALL cells to identify UTX binding sites across the genome. We then compared UTX binding sites (this study) with TAL1 binding sites (Data from Palii, 2011 GSE25000), and found a high degree of overlap between TAL1 and UTX in Jurkat T-All cells. Indeed, over 80% of TAL1 binding sites overlap with UTX.
|
|
|
Overall design |
Using ChIP-Seq, we identified UTX binding across the genome in Jurkat T-ALL cells. We then compared the binding sites of UTX and TAL1 (Data from Palii, 2011 GSE25000).
|
|
|
Contributor(s) |
Benyoucef A, Palii CG, Chu A, Brand M |
Citation(s) |
26944678 |
|
Submission date |
Jan 09, 2015 |
Last update date |
May 15, 2019 |
Organization |
Ottawa Hospital Research Institute |
Phone |
(613) 737-8899 -73255
|
Department |
Cellular and Molecular Medicine
|
Lab |
Ottawa Bioinformatics Core Facility
|
Street address |
501 Smyth Rd.
|
City |
Ottawa |
State/province |
ON |
ZIP/Postal code |
K1H 8L6 |
Country |
Canada |
|
|
Platforms (1) |
GPL11154 |
Illumina HiSeq 2000 (Homo sapiens) |
|
Samples (2) |
|
This SubSeries is part of SuperSeries: |
GSE72300 |
T-cell ALL in response to TAL1-KD, UTX-KD, and GSKJ4 treatment |
|
Relations |
Reanalysis of |
GSM614005 |
Reanalysis of |
GSM614003 |
BioProject |
PRJNA272133 |
SRA |
SRP051971 |